These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The potential role of stimulants in treating eating disorders. Keshen A; Bartel S; Frank GKW; Svedlund NE; Nunes A; Dixon L; Ali SI; Kaplan AS; Hay P; Touyz S; Romo-Nava F; McElroy SL Int J Eat Disord; 2022 Mar; 55(3):318-331. PubMed ID: 34846763 [TBL] [Abstract][Full Text] [Related]
6. Psychopharmacologic treatment of eating disorders: emerging findings. McElroy SL; Guerdjikova AI; Mori N; Keck PE Curr Psychiatry Rep; 2015 May; 17(5):35. PubMed ID: 25796197 [TBL] [Abstract][Full Text] [Related]
7. Reduction of bulimia nervosa symptoms after psychostimulant initiation in patients with comorbid ADHD: five case reports. Keshen A; Ivanova I Eat Disord; 2013; 21(4):360-9. PubMed ID: 23767675 [TBL] [Abstract][Full Text] [Related]
8. [Possible connection between eating disorders and ADHD. Bulimia can relieve ADHD symptoms, central nervous stimulants are of good help]. Ersson G; Klanger AR; Wallsten T; Nilsson KW; Lindström L Lakartidningen; 2007 May 2-8; 104(18):1402-5. PubMed ID: 17550013 [No Abstract] [Full Text] [Related]
9. A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa. Keshen AR; Dixon L; Ali SI; Helson T; Nunes A; Milliken H; Gamberg S; Sadek J; Kaplan A; McElroy SL Int J Eat Disord; 2021 May; 54(5):872-878. PubMed ID: 33534199 [TBL] [Abstract][Full Text] [Related]
10. The severity of ADHD and eating disorder symptoms: a correlational study. Stulz N; Hepp U; Gächter C; Martin-Soelch C; Spindler A; Milos G BMC Psychiatry; 2013 Feb; 13():44. PubMed ID: 23375103 [TBL] [Abstract][Full Text] [Related]
11. Attention-deficit/hyperactivity disorder symptoms and psychological comorbidity in eating disorder patients. Sala L; Martinotti G; Carenti ML; Romo L; Oumaya M; Pham-Scottez A; Rouillon F; Gorwood P; Janiri L Eat Weight Disord; 2018 Aug; 23(4):513-519. PubMed ID: 28534123 [TBL] [Abstract][Full Text] [Related]
13. The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Nazar BP; Bernardes C; Peachey G; Sergeant J; Mattos P; Treasure J Int J Eat Disord; 2016 Dec; 49(12):1045-1057. PubMed ID: 27859581 [TBL] [Abstract][Full Text] [Related]
14. Bulimia nervosa and attention deficit hyperactivity disorder: a possible role for stimulant medication. Dukarm CP J Womens Health (Larchmt); 2005 May; 14(4):345-50. PubMed ID: 15916509 [TBL] [Abstract][Full Text] [Related]
15. In brief: lisdexamfetamine (Vyvanse) for binge eating disorder. Med Lett Drugs Ther; 2015 Mar; 57(1464):42. PubMed ID: 25758546 [No Abstract] [Full Text] [Related]
16. Preliminary Evidence for the Off-Label Treatment of Bulimia Nervosa With Psychostimulants: Six Case Reports. Keshen A; Helson T J Clin Pharmacol; 2017 Jul; 57(7):818-822. PubMed ID: 28111772 [TBL] [Abstract][Full Text] [Related]
17. Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Bello NT; Yeomans BL Expert Opin Drug Saf; 2018 Jan; 17(1):17-23. PubMed ID: 29053927 [TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine: A Review in Binge Eating Disorder. Heo YA; Duggan ST CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566 [TBL] [Abstract][Full Text] [Related]
19. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe]. Häge A; Banaschewski T; Dittmann RW Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]